The DoD BAP Has (Finally) Convened

Bottom Line:

The BAP cleared a massive volume of previously stalled DoD P&T Committee decisions. To protect market share and prevent access disruptions, manufacturers must act now.

In late June 2026, the Department of Defense (DoD) Uniform Formulary Beneficiary Advisory Panel (BAP) held a public meeting that ended all Defense Health Agency (DHA) delays on final drug placement. The BAP systematically reviewed decisions from the eight previous Pharmacy and Therapeutics (P&T) Committee cycles. As highlighted in our 2026 Federal Market Access Reset, this process consolidated previously completed clinical recommendations into a single, high-volume review cycle.

The BAP serves as the statutory, public check under the Federal Advisory Committee Act, providing a structured, transparent venue for beneficiaries, providers, and professional organizations to offer feedback on proposed formulary adjustments. Initial clinical appraisals and financial assessments are initiated by the P&T Committee whenever a newly launched drug or a therapeutic class undergoes a re-examination. The BAP then examines the P&T Committee decisions. Once the BAP sends its final recommendations directly to the DHA Director, the DHA Director signs off on the final formulary decisions and the implementation phase begins. During the recent BAP hiatus, the P&T Committee maintained its quarterly meeting schedule; however, its decisions remained in a pending status until the BAP could complete its validations and, ultimately, submit its final recommendations to the DHA Director.

For pharmaceutical manufacturers, this resumption restores predictability to formulary decision-making within the DHA. As finalized decisions transition into implementation, manufacturers must shift their DoD strategies. Manufacturers must understand that these decisions will translate into patient copays on a rolling schedule tied to the first Wednesday occurring thirty to sixty days after committee minutes are signed by the Director of the DHA. Consequently, market dynamics for the earliest cycles are already shifting in real-time. To maintain strong portfolio alignment, manufacturer leadership teams should focus on two immediate tactical initiatives.

1. Field Readiness: Field teams and Medical Science Liaisons (MSLs) should be equipped with updated materials reflecting new prior authorization requirements or step-therapy protocols to ensure that appropriate patients receive access without administrative delay. Educational initiatives must prioritize clear, concise criteria mapping so that provider networks can navigate administrative thresholds seamlessly.

   
   

2. Portfolio Realignment: Market access teams must proactively align their portfolio strategies with the system's updated tier assignments. For products that have held a stable tier position through the pause, any movement (whether a step up or down) requires immediate attention. Manufacturers have a clear window to adjust their approach in this market, including a more precise evaluation of decision impacts to protect established market share or minimize volume erosion.

With the historical backlog fully addressed, the DHA is expected to return to its standard schedule. Products currently in a pre-launch cycle should be prepared for a return to the shorter review and implementation window from DHA. Launch plans must account for this compressed environment since there will be little room for reactive post-launch positioning.